Ipamorelin trial and route reference

Separate hormone response from benefit

A randomized placebo-controlled study in healthy men used intravenous ipamorelin to measure drug exposure and an acute GH response. This is pharmacology evidence. It does not show improved body composition, recovery, or longevity.

What the surgical trial studied

Beck and colleagues studied adults after small or large bowel resection in a double-blind phase 2 trial. The study enrolled 117 patients, with 114 in the safety and modified intent-to-treat populations. Patients received hospital intravenous infusions twice daily, beginning after surgery and continuing for up to seven days or discharge. This was a hospital research protocol. It does not establish a schedule for subcutaneous injections.

The main outcome was time to tolerate a standardized solid meal. The numerical difference between groups was not statistically significant. The trial also found no significant differences in its secondary efficacy analyses. Calling this faster recovery would overstate the result.

Check product and status

Neither published study specified the salt form. A product labeled ipamorelin acetate therefore cannot be assumed to match every detail of the tested drug. There is no FDA-approved ipamorelin product as of November 6, 2026. FDA identifies safety concerns and gaps in information for other injectable routes.

Record the clinician-directed plan

Keep the product name, salt if known, source, route, purpose, and clinician-documented schedule together. Record actual administration dates, symptoms, and any clinician-arranged monitoring. Keep intravenous trial findings separate from claims about a different route or a blended product.